882 related articles for article (PubMed ID: 22315264)
1. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Garcia DA; Baglin TP; Weitz JI; Samama MM
Chest; 2012 Feb; 141(2 Suppl):e24S-e43S. PubMed ID: 22315264
[TBL] [Abstract][Full Text] [Related]
2. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Hirsh J; Bauer KA; Donati MB; Gould M; Samama MM; Weitz JI
Chest; 2008 Jun; 133(6 Suppl):141S-159S. PubMed ID: 18574264
[TBL] [Abstract][Full Text] [Related]
3. [Heparin induced thrombocytopenia and anticoagulation in renal replacemant therapy].
Steinfeldt T; Rolfes C
Anasthesiol Intensivmed Notfallmed Schmerzther; 2008 Apr; 43(4):304-10; quiz 312. PubMed ID: 18409125
[TBL] [Abstract][Full Text] [Related]
4. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Hirsh J; Raschke R
Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
[TBL] [Abstract][Full Text] [Related]
5. Treatment of heparin-induced thrombocytopenia in cardiovascular patients.
Matthai WH
Expert Opin Pharmacother; 2006 Feb; 7(3):267-76. PubMed ID: 16448321
[TBL] [Abstract][Full Text] [Related]
6. Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery.
Murphy GS; Marymont JH
J Cardiothorac Vasc Anesth; 2007 Feb; 21(1):113-26. PubMed ID: 17289495
[No Abstract] [Full Text] [Related]
7. Heparin-induced thrombocytopenia and thrombosis.
Patel VP; Bong M; Di Cesare PE
Am J Orthop (Belle Mead NJ); 2007 May; 36(5):255-60. PubMed ID: 17571830
[TBL] [Abstract][Full Text] [Related]
8. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management.
Shantsila E; Lip GYH; Chong BH
Chest; 2009 Jun; 135(6):1651-1664. PubMed ID: 19497901
[TBL] [Abstract][Full Text] [Related]
9. Management of thrombotic and cardiovascular disorders in the new millenium.
Fareed J; Hoppensteadt DA; Bick RL
Clin Appl Thromb Hemost; 2003 Apr; 9(2):101-8. PubMed ID: 12812377
[TBL] [Abstract][Full Text] [Related]
10. An update on heparins at the beginning of the new millennium.
Fareed J; Hoppensteadt DA; Bick RL
Semin Thromb Hemost; 2000; 26 Suppl 1():5-21. PubMed ID: 11011802
[TBL] [Abstract][Full Text] [Related]
11. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
[TBL] [Abstract][Full Text] [Related]
12. Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia.
Jeske WP; Walenga JM
Curr Opin Investig Drugs; 2002 Aug; 3(8):1171-80. PubMed ID: 12211410
[TBL] [Abstract][Full Text] [Related]
13. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation.
Hoppensteadt D; Walenga JM; Fareed J; Bick RL
Hematol Oncol Clin North Am; 2003 Feb; 17(1):313-41. PubMed ID: 12627673
[TBL] [Abstract][Full Text] [Related]
14. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures.
Kodityal S; Manhas AH; Udden M; Rice L
Eur J Haematol; 2003 Aug; 71(2):109-13. PubMed ID: 12890149
[TBL] [Abstract][Full Text] [Related]
15. Effects of argatroban, danaparoid, and fondaparinux on trombin generation in heparin-induced thrombocytopenia.
Tardy-Poncet B; Combe M; Piot M; Chapelle C; Akrour M; Tardy B
Thromb Haemost; 2013 Mar; 109(3):504-9. PubMed ID: 23328916
[TBL] [Abstract][Full Text] [Related]
16. Argatroban and bivalirudin compared to unfractionated heparin in preventing thrombus formation on mechanical heart valves. Results of an in-vitro study.
Maegdefessel L; Linde T; Michel T; Hamilton K; Steinseifer U; Friedrich I; Schubert S; Hauroeder B; Raaz U; Buerke M; Werdan K; Schlitt A
Thromb Haemost; 2009 Jun; 101(6):1163-9. PubMed ID: 19492162
[TBL] [Abstract][Full Text] [Related]
17. Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia.
Schindewolf M; Steindl J; Beyer-Westendorf J; Schellong S; Dohmen PM; Brachmann J; Madlener K; Pötzsch B; Klamroth R; Hankowitz J; Banik N; Eberle S; Müller MM; Kropff S; Lindhoff-Last E
J Am Coll Cardiol; 2017 Nov; 70(21):2636-2648. PubMed ID: 29169470
[TBL] [Abstract][Full Text] [Related]
18. Hirudin in heparin-induced thrombocytopenia.
Lubenow N; Greinacher A
Semin Thromb Hemost; 2002 Oct; 28(5):431-8. PubMed ID: 12420238
[TBL] [Abstract][Full Text] [Related]
19. Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors.
Lepor NE
Rev Cardiovasc Med; 2007; 8 Suppl 3():S9-17. PubMed ID: 17917621
[TBL] [Abstract][Full Text] [Related]
20. Heparin-induced thrombocytopenia--therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes.
Krauel K; Fürll B; Warkentin TE; Weitschies W; Kohlmann T; Sheppard JI; Greinacher A
J Thromb Haemost; 2008 Dec; 6(12):2160-7. PubMed ID: 18983520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]